Literature DB >> 33716332

Implementation of tuberculosis preventive treatment among people living with HIV, South Sudan.

Andrew T Boyd1, Dennis Kenyi Lodiongo2, John Mondi Benson2, Shambel Aragaw3, Margaret Semira Pasquale3, Habtamu Ayalneh3, Robert Olemukan3, Isaac Avaku4, Nicholas Baabe5, Victoria Achut6, Helen Chun1, Sudhir Bunga2.   

Abstract

OBJECTIVE: To describe an intervention to scale up tuberculosis preventive treatment for people living with human immunodeficiency virus (HIV) in South Sudan, 2017-2020.
METHODS: Staff of the health ministry and United States President's Emergency Plan for AIDS Relief designed an intervention targeting the estimated 30 400 people living with HIV on antiretroviral therapy across South Sudan. The intervention comprised: (i) developing sensitization and operational guidance for clinicians to put tuberculosis preventive treatment delivery into clinical practice; (ii) disseminating monitoring and evaluation tools to document scale-up; (iii) implementing a programmatic pilot of tuberculosis preventive treatment; and (iv) identifying a mechanism for procurement and delivery of isoniazid to facilities dispensing tuberculosis preventive treatment. Staff aggregated routine programme data from facility registers on the numbers of people living with HIV who started on tuberculosis preventive treatment across all clinical sites providing this treatment during July 2019-March 2020.
FINDINGS: Tuberculosis preventive treatment was implemented in 13 HIV treatment sites during July-October 2019, then in 26 sites during November 2019-March 2020. During July 2019-March 2020, 6503 people living with HIV started tuberculosis preventive treatment.
CONCLUSION: Lessons for other low-resource settings may include supplementing national guidelines with health ministry directives, clinician guidance and training, and an implementation pilot. A cadre of field supervisors can rapidly disseminate a standardized approach to implementation and monitoring of tuberculosis preventive treatment, and this approach can be used to strengthen other tuberculosis-HIV services. Procuring a reliable and steady supply of tuberculosis preventive treatment medication is crucial. (c) World Health Organization (WHO) 2021. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33716332      PMCID: PMC7947931          DOI: 10.2471/BLT.20.254789

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  7 in total

1.  Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons.

Authors:  Timothy R Sterling; Nigel A Scott; Jose M Miro; Guilherme Calvet; Alberto La Rosa; Rosa Infante; Michael P Chen; Debra A Benator; Fred Gordin; Constance A Benson; Richard E Chaisson; M Elsa Villarino
Journal:  AIDS       Date:  2016-06-19       Impact factor: 4.177

2.  Policies, practices and barriers to implementing tuberculosis preventive treatment-35 countries, 2017.

Authors:  D Surie; J D Interrante; I Pathmanathan; M R Patel; G Anyalechi; J S Cavanaugh; H L Kirking
Journal:  Int J Tuberc Lung Dis       Date:  2019-12-01       Impact factor: 2.373

3.  One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.

Authors:  Susan Swindells; Ritesh Ramchandani; Amita Gupta; Constance A Benson; Jorge Leon-Cruz; Noluthando Mwelase; Marc A Jean Juste; Javier R Lama; Javier Valencia; Ayotunde Omoz-Oarhe; Khuanchai Supparatpinyo; Gaerolwe Masheto; Lerato Mohapi; Rodrigo O da Silva Escada; Sajeeda Mawlana; Peter Banda; Patrice Severe; James Hakim; Cecilia Kanyama; Deborah Langat; Laura Moran; Janet Andersen; Courtney V Fletcher; Eric Nuermberger; Richard E Chaisson
Journal:  N Engl J Med       Date:  2019-03-14       Impact factor: 91.245

4.  Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial.

Authors:  Anani Badje; Raoul Moh; Delphine Gabillard; Calixte Guéhi; Mathieu Kabran; Jean-Baptiste Ntakpé; Jérôme Le Carrou; Gérard M Kouame; Eric Ouattara; Eugène Messou; Amani Anzian; Albert Minga; Joachim Gnokoro; Patrice Gouesse; Arlette Emieme; Thomas-d'Aquin Toni; Cyprien Rabe; Baba Sidibé; Gustave Nzunetu; Lambert Dohoun; Abo Yao; Synali Kamagate; Solange Amon; Amadou-Barenson Kouame; Aboli Koua; Emmanuel Kouamé; Marcelle Daligou; Denise Hawerlander; Simplice Ackoundzé; Serge Koule; Jonas Séri; Alex Ani; Fassery Dembélé; Fatoumata Koné; Mykayila Oyebi; Nathalie Mbakop; Oyewole Makaila; Carolle Babatunde; Nathaniel Babatunde; Gisèle Bleoué; Mireille Tchoutedjem; Alain-Claude Kouadio; Ghislaine Sena; Sahinou-Yediga Yededji; Sophie Karcher; Christine Rouzioux; Abo Kouame; Rodrigue Assi; Alima Bakayoko; Serge K Domoua; Nina Deschamps; Kakou Aka; Thérèse N'Dri-Yoman; Roger Salamon; Valérie Journot; Hughes Ahibo; Timothée Ouassa; Hervé Menan; André Inwoley; Christine Danel; Serge P Eholié; Xavier Anglaret
Journal:  Lancet Glob Health       Date:  2017-11       Impact factor: 26.763

5.  Scaling up isoniazid preventive therapy in Zimbabwe: has operational research influenced policy and practice?

Authors:  K C Takarinda; R C Choto; T Mutasa-Apollo; C Chakanyuka-Musanhu; C Timire; A D Harries
Journal:  Public Health Action       Date:  2018-12-21

6.  Taking tuberculosis preventive therapy implementation to national scale: the Nigerian PEPFAR Program experience.

Authors:  B Odume; S C Meribe; T Odusote; M Ifunanya; H Debem; I Amazue-Ezeuko; O Ogbanufe; Y Adamu; D Onotu
Journal:  Public Health Action       Date:  2020-03-21

7.  A prospective cohort study of outcomes for isoniazid prevention therapy: a nested study from a national QI collaborative in Uganda.

Authors:  Simon Sensalire; Esther Karungi Karamagi Nkolo; Juliana Nabwire; Anna Lawino; Dithan Kiragga; Martin Muhire; Herbert Kadama; Cordelia Katureebe; Proscovia Namuwenge; Joshua Musinguzi; Jacqueline Calnan; Dejene Seyoum
Journal:  AIDS Res Ther       Date:  2020-05-27       Impact factor: 2.250

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.